Clinical trials: Neoadjuvant Radiotherapy
Resectable Pancreatic Adenocarcinoma, Borderline Resectable Pancreatic Adenocarcinoma
Neoadjuvant Stereotactic Ablative Radiotherapy for Pancreatic Ductal Adenocarcinoma
Pancreatic cancer (PC) is expected to be the third leading cause of cancer death in Canada in 2019 [1]. Localized pancreatic cancer may be classified as resectable, borderline resectable, or locally advanced.
- Trial name
- ANSR-PDAC (NCT04915417)
- Testing
- Stereotactic Ablative Body Radiotherapy (SABR)
- Volunteers
- 30 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Urothelial Carcinoma of the Renal Pelvis and Ureter, Neoadjuvant Therapy
Neoadjuvant Disitamab Vedotin, Toripalimab, and Radiotherapy for High-risk UTUC ( LUXUS07.1 )
This is an open-label, single-arm, single-cohort, prospective clinical study evaluating neoadjuvant antibody-drug conjugate therapy combined with immunotherapy and sequential radiotherapy followed by radical surgery in patients…
- Trial name
- LUXUS0701 (NCT07720921)
- Testing
- Neoadjuvant radiotherapy, ADC + PD1 monoclonal antibody
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Peking University First Hospital
Soft Tissue Sarcoma
Trial of Neoadjuvant Conformal Radiotherapy Plus Sorafenib for Patients With Soft Tissue Sarcoma of the Extremity and Body Wall
Patients will receive neoadjuvant sorafenib (investigational agent) in combination with preoperative external beam conformal radiotherapy (50 Gy in 25 fractions) for localized, large soft tissue sarcomas of the extremity and body…
- Trial name
- NCT00864032
- Testing
- Sorafenib
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- University of California, Davis
Rectal Neoplasms
Effective Study of Preoperative Short-course Radiotherapy for the Advanced Resectable Rectal Cancer
The local recurrence of rectal cancer is one of the main problem that fail the treatment. The preoperative neoadjuvant (chemo)radiotherapy has been confirmed to reduce the local recurrence rate,especially in the advanced rectal…
- Trial name
- NCT01437514
- Testing
- preoperative short-course radiotherapy
- Where
- 4 sites in China
- Volunteers
- 410 people
- Sponsor
- West China Hospital
NSCLC, Neoadjuvant Immunotherapy
Low Dose Radiotherapy Combined With Sintilimab and Chemotherapy as Neoadjuvant Therapy for Stage II-III NSCLC
To evaluate efficacy and safety of low dose radiotherapy combined with sintilimab and platinum based chemotherapy as neoadjuvant therapy for stage II-III Non-Small Cell Lung Cancer
- Conditions
- NSCLC, Neoadjuvant Immunotherapy, Low Dose Radiotherapy, Sintilimab
- Trial name
- NCT06714708
- Testing
- Experimental, Active comparator
- Where
- China
- Volunteers
- 86 people
- Sponsor
- Anhui Provincial Cancer Hospital
Breast Neoplasm Malignant Female
Omission of Local Therapies in Women Patients With HER2-positive or Triple-negative Breast Cancer
HER2-positive and Triple-negative are subtypes of breast cancer more sensitive to systemic therapies, where the complete pathological response rate may be higher than 50%.
- Trial name
- OLT (NCT06938724)
- Testing
- Omission of local therapies
- Where
- Italy
- Volunteers
- 152 people
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Gastric Cardia Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
Pembrolizumab, Combination Chemotherapy, and Radiation Therapy Before Surgery in Treating Adult Patients With Locally Advanced Gastroesophageal Junction or Gastric Cardia Cancer That Can Be Removed by Surgery
This phase Ib/II trial studies the side effects and best way to give pembrolizumab with combination chemotherapy and radiation therapy before surgery and to see how well it works in treating adult patients with gastroesophageal…
- Conditions
- Gastric Cardia Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Stage IB Gastric Cancer AJCC v7, Stage II Gastric Cancer AJCC v7
- Trial name
- NCT02730546
- Testing
- Carboplatin, Computed Tomography, Fluorouracil
- Where
- 2 sites in United States
- Volunteers
- 31 people
- Sponsor
- Mayo Clinic
Pancreas Neoplasm Malignant Resectable
Phase II Study of Chemo-Radiotherapy in Patients With Resectable and Borderline Resectable Pancreatic Cancer
To evaluate the safety and effectiveness of a novel neoadjuvant treatment strategy incorporating 5-fluorouracil/leucovorin with oxaliplatin ( FOLFOX )chemotherapy in combination with chemo-radiation with gemcitabine.
- Trial name
- NCT02243358
- Testing
- Folfox6, Gemcitabine, Radiation Therapy
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Henry Ford Health System
Locally Advanced Pancreatic Cancer, Borderline Pancreatic Inoperable Cancer
Folfirinox or Gemcitabine-Nab Paclitaxel Followed by Stereotactic Body Radiotherapy for Locally Advanced Pancreatic Cancer
This study will implement a new treatment regimen for patients with advanced and inoperable pancreatic cancer using chemotherapy combinations of Folfirinox or gemcitabine-nab paclitaxel (abraxane) followed by a short course of…
- Conditions
- Locally Advanced Pancreatic Cancer, Borderline Pancreatic Inoperable Cancer, Pancreatic Cancer
- Trial name
- NCT03600623
- Testing
- Folfirinox, Gemcitabine nab-Paclitaxel
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of Alabama at Birmingham
Non Small Cell Lung Cancer, Stage III Lung Cancer
Post-operative Radiotherapy After Neodjuvant Chemo-immunotherapy and Surgery in Stage III NSCLC
This study investigates whether postoperative radiotherapy (PORT) improves outcomes for patients with stage III non-small cell lung cancer (NSCLC) who have residual disease after neoadjuvant chemo-immunotherapy and surgery.
- Trial name
- RESCUE (NCT06878274)
- Testing
- Post-operative radiotherapy
- Where
- Canada
- Volunteers
- 118 people
- Sponsor
- Centre hospitalier de l'Université de Montréal (CHUM)
Rectal Cancer
Adaptive Boost Radiotherapy to Primary Lesions and Positive Nodes in the Neoadjuvant Treatment of Locally Advanced Rectal Cancer
This prospective, single-center, randomized controlled trial evaluates whether online adaptive radiotherapy (ART) with a sequential boost to both the primary rectal tumor and clinically involved lymph nodes improves pathologic…
- Trial name
- NCT06246344
- Testing
- Online Adaptive Radiotherapy With Sequential Boost, Conventional Non-Adaptive IMRT, Capecitabine
- Where
- China
- Volunteers
- 128 people
- Sponsor
- Shandong Cancer Hospital and Institute
Neoadjuvant Therapies, Immune Checkpoint Therapy
Node-Sparing Hypofractionated Radiotherapy Plus Chemotherapy and PD-1 Inhibitor in pMMR/MSS High-Risk Locally Advanced Colon Cancer: A Prospective, Randomized, Phase II Trial
Most colorectal cancers are microsatellite stable (MSS) or mismatch repair-proficient (pMMR) subtypes, which show limited efficacy to PD-1 inhibitors.
- Conditions
- Neoadjuvant Therapies, Immune Checkpoint Therapy, Radiotherapy
- Trial name
- MODIFI-CC (NCT07230639)
- Testing
- Node-Sparing Radiotherapy(25Gy/5F) plus Chemotherapy and PD-1 inhibitor, Node-Sparing Radiotherapy(24Gy/4F) plus Chemotherapy and PD-1 inhibitor
- Where
- China
- Volunteers
- 52 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
Head and Neck Squamous Cell Carcinoma, Radiotherapy
Selected De-escalation Radiotherapy for Postoperative Head and Neck Squamous Cell Carcinoma
This study is looking to see if sintilimab, an anti-PD-1 McAb given with cisplatinum and paclitaxel (2 chemotherapy agents) during induction therapy in advanced head and neck squamous cell carcinoma can significantly shrink the…
- Conditions
- Head and Neck Squamous Cell Carcinoma, Radiotherapy, Immunotherapy, Surgery
- Trial name
- iCSDeR (NCT05476965)
- Testing
- induction therapy; surgery; radiotherapy
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Hubei Cancer Hospital
Locally Advanced Rectal Cancer (LARC), Mismatch Repair-Proficient (pMMR) Rectal Cancer
QL1706 With Short-Course Radiotherapy and Chemotherapy for MSS Rectal Cancer
This is a multicenter, prospective, phase II study evaluating total neoadjuvant therapy (TNT) consisting of short-course radiotherapy (SCRT; 5×5 Gy) followed by QL1706 (a bifunctional MabPair antibody targeting PD-1 and CTLA-4…
- Conditions
- Locally Advanced Rectal Cancer (LARC), Mismatch Repair-Proficient (pMMR) Rectal Cancer, Non-metastatic Rectal Cancer
- Trial name
- NCT07175636
- Testing
- Drug: QL1706 Drug: mFOLFOX6 Radiation: Short-Course Radiotherapy (SCRT)
- Volunteers
- 66 people
- Sponsor
- Sun Yat-sen University
Gastric Cancer, Effects of Chemotherapy
Therapeutic Individualization for Patients With Locally Advanced Gastric and Gastroesophageal Cancer
The purpose of this study is to evaluate whether the R0 rate, pathological response degree, patterns of recurrence and long-term outcomes may be initially predicted in patients with locally advanced gastroesophageal junction and…
- Conditions
- Gastric Cancer, Effects of Chemotherapy, Surgery
- Trial name
- NCT02454673
- Where
- Spain
- Volunteers
- 121 people
- Sponsor
- Clinica Universidad de Navarra, Universidad de Navarra
Mesothelioma, Solitary Fibrous Tumor of the Pleura
Chemotherapy Followed by Surgery and Neoadjuvant Hemothoracic Intensity Modified Radiation Therapy (IMRT) for Patients With Malignant Pleural Mesothelioma
The purpose of this study is to determine the response rate and overall survival in patients that have been diagnosed with mesothelioma and will undergo chemotherapy, surgery and intensity modified radiation therapy (IMRT) as…
- Trial name
- NCT02613312
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Mayo Clinic
Colorectal Cancer
Oxaliplatin, Capecitabine, and Radiation Therapy in Treating Patients With Locally Advanced Cancer of the Rectum
RATIONALE: Drugs used in chemotherapy, such as oxaliplatin and capecitabine, work in different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00086931
- Testing
- capecitabine, oxaliplatin, conventional surgery
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Roswell Park Cancer Institute
Rectal Adenocarcinoma
ExIST Study of LY2157299 (Galunisertib) in Rectal Cancer
The purpose of this study is to see how effective and safe LY2157299, in combination with chemotherapy and radiation therapy, might be in treating rectal cancer.
- Trial name
- NCT02688712
- Testing
- LY2157299, Capecitabine, Fluorouracil
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Providence Health & Services
Cervical Cancer
Comparing Study Between Concurrent Chemoradiation and New Combination Treatment in Cervical Cancer Patients
The purpose of this study is: to compare the effectiveness between the new strategy of treatment (given cis-platinum plus gemcitabine-neoadjuvant chemotherapy followed by surgery),and standard treatment (given…
- Trial name
- TGOCphaseIII (NCT01000415)
- Testing
- Neoadjuvant chemotherapy followed by surgery
- Where
- Thailand
- Volunteers
- 824 people
- Sponsor
- Thai Gynecologic Oncology Collaborative Group
Pancreatic Cancer
A Study of Gemcitabine/Nab-paclitaxel and Radiation Therapy Followed by Surgery in Patients With Advanced Pancreatic Cancer
This is a phase 1 (the first phase in testing a new drug, to see how safe a new drug or new indication/population ) and phase 2 (the second phase in testing a new drug or new indication/population to see how effective the drug…
- Trial name
- NCT02481635
- Testing
- Gemcitabine, Nab-paclitaxel, Radiation Therapy
- Where
- Canada
- Volunteers
- 11 people
- Sponsor
- University Health Network, Toronto